Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
DYAI
$0.808
$
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Next Earnings
2026-02-25
Beta
1.275
Average Volume
Market Cap
Last Dividend
CIK
0001213809
ISIN
US26745T1016
CUSIP
26745T101
CEO
Mark A. Emalfarb
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
6
IPO Date
2008-01-16
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin | JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals (“Proliant”), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announced the commercial launch of AlbuFree™ DX, a recombinant human albumin (rHA) product produced using Dyadic's proprietary filamentous fungal expression technology. | GlobeNewsWire | 2026-02-17 07:25:00 |
| Dyadic International (NASDAQ:DYAI) Share Price Crosses Below 50 Day Moving Average – Should You Sell? | Dyadic International Inc. (NASDAQ: DYAI - Get Free Report)'s share price crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $0.94 and traded as low as $0.85. Dyadic International shares last traded at $0.89, with a volume of 33,590 shares. Wall Street Analysts Forecast | Defense World | 2026-01-16 04:52:55 |
| Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets | JUPITER, Fla. , Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications, diverse commercial applications, today announced a significant expansion of its collaboration with Fermbox Bio, a biotech research and manufacturing company developing and delivering sustainable bio-based products through precision fermentation and advanced biotechnology tools. | Globe News Wire | 2025-12-17 07:20:00 |
| Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins | JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets today announced that it has entered into a commercial agreement with Opes Diagnostics Limited (“Opes”) to support the commercial launch of Dyadic's recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products for use in serum-free cell culture media applications in the life science, food and nutrition markets. | GlobeNewsWire | 2025-12-15 07:20:00 |
| Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript | Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript | Seeking Alpha | 2025-12-09 10:57:08 |
| Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR) | Dyadic International (NASDAQ: DYAI - Get Free Report) and Kezar Life Sciences (NASDAQ: KZR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation. Profitability This table compares Dyadic International | Defense World | 2025-12-03 02:20:44 |
| Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets | JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets, and BRIG BIO (official legal entity The Protein Collective B.V. | GlobeNewsWire | 2025-12-01 07:25:00 |
| Bandera Partners LLC Has $1.37 Million Holdings in Dyadic International Inc. $DYAI | Bandera Partners LLC decreased its position in shares of Dyadic International Inc. (NASDAQ: DYAI) by 11.7% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,383,308 shares of the biotechnology company's stock after selling 183,600 shares during the quarter. Dyadic International | Defense World | 2025-11-25 03:36:50 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-12-29 | 2025-12-23 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-10-07 | 2025-10-07 | View Filing |
| 4 | 2025-09-17 | 2025-09-17 | View Filing |
| 8-K | 2025-09-16 | 2025-09-16 | View Filing |
| SC 13G/A | 2025-08-19 | 2025-08-19 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 424B5 | 2025-07-31 | 2025-07-31 | View Filing |
| 424B5 | 2025-07-30 | 2025-07-30 | View Filing |
| 8-K | 2025-07-23 | 2025-07-23 | View Filing |
| 8-K | 2025-07-23 | 2025-07-23 | View Filing |
| 8-K | 2025-07-02 | 2025-07-02 | View Filing |
| 8-K | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-24 | 2025-06-24 | View Filing |
| 4 | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-02 | 2025-06-02 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-05 | 2025-05-05 | View Filing |
| DEFA14A | 2025-04-29 | 2025-04-29 | View Filing |
| DEF 14A | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| EFFECT | 2025-04-03 | 2025-04-03 | View Filing |
| S-3 | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-26 | 2025-03-26 | View Filing |
| 10-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-03-07 | 2025-03-07 | View Filing |
| SC 13G | 2025-02-06 | 2025-02-06 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 8-K | 2024-11-26 | 2024-11-26 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-10-08 | 2024-10-08 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-07-02 | 2024-07-02 | View Filing |
| 8-K | 2024-07-02 | 2024-07-02 | View Filing |
| 4 | 2024-06-13 | 2024-06-13 | View Filing |
| 8-K | 2024-06-11 | 2024-06-11 | View Filing |
| 4 | 2024-05-23 | 2024-05-23 | View Filing |
| 8-K | 2024-05-14 | 2024-05-14 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| EFFECT | 2024-05-08 | 2024-05-08 | View Filing |
| S-3 | 2024-04-24 | 2024-04-24 | View Filing |
| ARS | 2024-04-24 | 2024-04-24 | View Filing |
| DEFA14A | 2024-04-24 | 2024-04-24 | View Filing |
| DEF 14A | 2024-04-24 | 2024-04-24 | View Filing |
| 4 | 2024-04-15 | 2024-04-15 | View Filing |
| 4 | 2024-04-15 | 2024-04-15 | View Filing |
| 4 | 2024-04-15 | 2024-04-15 | View Filing |
| 4 | 2024-04-15 | 2024-04-15 | View Filing |
| 4 | 2024-04-15 | 2024-04-15 | View Filing |
| 4 | 2024-04-15 | 2024-04-15 | View Filing |
| 4 | 2024-04-15 | 2024-04-15 | View Filing |
| 10-K | 2024-03-28 | 2024-03-28 | View Filing |
| 8-K | 2024-03-28 | 2024-03-28 | View Filing |
| 8-K | 2024-03-11 | 2024-03-11 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Genetic Strat | 88.22% | 1.01 | 593 | 0.04 | 0.05 | 86.92 |
| Macd Rsi Composite Strategy | 61.97% | 0.92 | 21 | 0.06 | 0.15 | 60.67 |
| Williams PercentR Strategy | 54.82% | 0.99 | 241 | 0.04 | 0.08 | 53.52 |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | x |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |